+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are studying whether using a drug-eluting stent DES combined with aggressive medical treatment is more effective at preventing stroke recurrence within one year compared to standard medical treatment alone in patients with symptomatic intracranial atherosclerotic disease. This prospective, multi-center trial randomly assigns participants to either the stent plus aggressive medication group or the standard treatment group to evaluate safety and stroke prevention outcomes. The study compares two groups one receiving the Maurora Sirolimus Eluting Stent implantation plus aggressive medical treatment, which includes aspirin daily throughout follow-up, clopidogrel or ticagrelor for six months, and management of risk factors like hypertension and diabetes the other receiving standard medical treatment with aspirin daily, clopidogrel or ticagrelor for three months, and similar risk factor management. The device used is a balloon-expandable sirolimus-eluting stent delivered via catheter. Follow-up lasts 12 months after enrollment. Participants will undergo regular assessments including monitoring for stroke or death within 30 days after enrollment or procedures, ischemic stroke occurrence up to one year, bleeding events, imaging to check for vessel narrowing, and functional status evaluations. Safety and effectiveness are closely tracked through clinical visits and tests over the 12-month period. The study aims to provide detailed data on stroke recurrence prevention and treatment safety in this patient population.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
18 locations
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
I

Actively Recruiting

Researchers are conducting a multicenter observational study called the IMPACT COPD Cohort China to better understand chronic obstructive pulmonary disease COPD and its common coexisting conditions. The study focuses on how COPD and these additional health problems interact and affect symptoms, flare-ups, hospital visits, and disease progression over time. The goal is to create real-world evidence to improve integrative management combining Chinese and Western medicine. Participants are observed without assigned treatments. The study combines regular clinical assessments like symptom checks, questionnaires, lung function tests, imaging, and biomarker analysis with continuous digital monitoring of heart rate, blood pressure, activity, sleep, and other physiological and behavioral factors. Traditional Chinese Medicine evaluations including tongue, pulse, and facial diagnostics also contribute to a comprehensive health profile. This approach supports the development of risk prediction models and early warning systems for COPD exacerbations and comorbidities across different care settings. During the study, participants undergo ongoing evaluations and data collection over up to 36 months. Researchers monitor the yearly rate of COPD flare-ups and the occurrence of related comorbid conditions such as hypertension, heart diseases, and diabetes. The long-term follow-up includes detailed clinical and digital health data to guide future integrated care strategies. Participation involves routine clinical visits and continuous digital monitoring to assess health status and disease progression.

Age: 40Years - 85YearsAll Genders
4 locations
E

Actively Recruiting

Healthy Volunteer

Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
26 locations
P

Actively Recruiting

Researchers are evaluating a fixed-dose combination strategy, known as the Polypill Approach for Multiple Cardiovascular Risk Factors PACIF, to manage hypertension, dyslipidemia, and type 2 diabetes in adults aged 50 to 75 years without prior cardiovascular disease in China. This multicenter randomized controlled trial aims to see if this polypill approach can improve 10-year cardiovascular disease risk and reduce major cardiovascular events and cognitive decline compared with usual care. Participants will be randomly assigned to receive either the fixed-dose combination strategy or usual care. The intervention includes eight fixed-dose formulations combining blood pressure-lowering, lipid-lowering, and glucose-lowering medications such as olmesartan medoxomilamlodipine, rosuvastatin, ezetimibe, dapagliflozin, and indapamide in selected formulations. Treatment is adjusted based on blood pressure, lipid, and glucose targets, with additional medications allowed if targets are not met. During the study, participants will be monitored over months to assess changes in cardiovascular risk factors, achievement of treatment goals, medication adherence, and cognitive outcomes such as dementia. The primary outcomes include estimated 10-year cardiovascular risk at 12 months and a composite of major cardiovascular events at 36 months. Safety and quality of life will also be evaluated throughout the trial lasting up to 36 months, with ongoing follow-up and assessments.

Age: 50Years - 75YearsAll GendersPhase Not Applicable
15 locations
C

Actively Recruiting

Researchers are comparing the safety and effectiveness of two intravenous drugs, urokinase and alteplase, in treating acute ischemic stroke AIS within 6 hours of symptom onset. Alteplase is currently recommended within 4.5 hours but is costly, while urokinase is less expensive. Existing studies show mixed results for urokinase, so this study aims to gather real-world data on both treatments, including safety, effectiveness, and economic impact, to help inform future stroke care. The study involves patients receiving either intravenous urokinase or alteplase as treatment for AIS. Researchers will observe and analyze these treatments in multiple centers across the nation, comparing outcomes and exploring different urokinase dosages and related risk factors. Alteplase serves as the active control group to evaluate urokinase against current standards. Participants will be monitored for their functional recovery using the modified Rankin scale at 90 days after treatment to assess good outcomes. The study includes clinical diagnosis confirmation, imaging to exclude hemorrhage, and patient consent procedures. Data on safety, effectiveness, and costs will be collected, with follow-up assessments at day 90. The trial aims to provide comprehensive information over its duration until December 2026.

Age: 18Years +All Genders
16 locations